NasdaqGS:IBRXBiotechs
Why ImmunityBio (IBRX) Is Down 12.9% After FDA Warning Letter And Investor Lawsuit Over Anktiva
In March 2026, ImmunityBio faced regulatory and legal pressure as an FDA warning letter over alleged misleading Anktiva promotions was followed by a securities class action lawsuit claiming investors were misled about the drug’s capabilities and the company’s prospects.
At the same time, ANKTIVA advanced clinically and commercially, with an Independent Data Monitoring Committee confirming adequate power for the pivotal QUILT-2.005 trial and new approvals and guideline recognition extending...